RxDoctor Payments Data

Melissa Gross

Family · Exton, PANPI 1740675008

Payments from drug & device makers

$2,148in general payments, 2019–2025

Across 96 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$408
  • Fusion Orthopedics USA, LLC$343
  • Regeneron Healthcare Solutions, Inc.$327
  • Novartis$190
  • Covis Pharma GmbH$156
  • Optinose US, Inc.$92
  • plus $633 from 12 others

What the payments were for

  • Food & beverage$2,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,148 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$22,724
Medicare patients
117
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$25,190
JanuviaSitagliptin Phosphate17$19,619
XareltoRivaroxaban13$12,076
Spiriva RespimatTiotropium Bromide20$9,961
Lidocaine15$2,505
Albuterol Sulfate HfaAlbuterol Sulfate85$2,094
Rosuvastatin Calcium95$1,968
Omeprazole131$1,857
SynthroidLevothyroxine Sodium22$1,372
Atorvastatin Calcium105$1,296
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,237
Lamotrigine18$1,044
Fluticasone Propionate63$993
Levetiracetam21$903
Montelukast Sodium55$875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat$85$9,96120 claims
AbbVieSynthroid$68$1,37222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.

Other family in Exton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →